成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 163222-33-1 Chemical Structure| 163222-33-1
Chemical Structure| 163222-33-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 163222-33-1

,{[proInfo.pro_purity]}

Ezetimibe is a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. It's also a Niemann-Pick C1-like1 (NPC1L1) inhibitor and Nrf2 activator.

Synonyms: SCH 58235; Ezetrol; Ezetimibe, Zetia, Ezetrol,

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of Ezetimibe

CAS No. :163222-33-1
Formula : C24H21F2NO3
M.W : 409.43
SMILES Code : O=C1N(C2=CC=C(F)C=C2)[C@H](C3=CC=C(O)C=C3)[C@H]1CC[C@@H](C4=CC=C(F)C=C4)O
Synonyms :
SCH 58235; Ezetrol; Ezetimibe, Zetia, Ezetrol,
MDL No. :MFCD00937872
InChI Key :OLNTVTPDXPETLC-XPWALMASSA-N
Pubchem ID :150311

Safety of Ezetimibe

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H372-H410
Precautionary Statements:P273-P301+P312+P330-P305+P351+P338-P314
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description Reference
AS patient PBMCs 20 μM 1 day To investigate the effect of Ezetimibe on Th17 cell differentiation in AS patient PBMCs, results showed that Ezetimibe significantly reduced the number of Th17 cells. PMC9428320
Human primary lung fibroblasts (hLFs) 20 μM 24 hours Ezetimibe inhibited TGFβ1-induced myofibroblast differentiation, restored intracellular cholesterol distribution, and suppressed fibrotic gene expression through the mTORC1-autophagy axis. PMC11096666
Mouse primary lung fibroblasts (mLFs) 20 μM 24 hours Ezetimibe inhibited TGFβ1-induced myofibroblast differentiation, restored intracellular cholesterol distribution, and suppressed fibrotic gene expression through the mTORC1-autophagy axis. PMC11096666
Mouse spleen cells 10 and 20 μM 3 days To investigate the effect of Ezetimibe on immune cell differentiation, results showed that Ezetimibe increased the number of Treg cells and reduced the number of Th17 and Th1 cells. PMC9428320
Rat mesenteric artery smooth muscle cells 5–50 μM To explore the direct vascular effect of Ezetimibe on rat mesenteric arteries, it was found that Ezetimibe induced concentration-dependent vasodilation. PMC10531054

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
C57BL/6J mice Bleomycin-induced pulmonary fibrosis model Oral gavage 2 mg/kg Three times a week for 21 days Ezetimibe ameliorated bleomycin-induced pulmonary fibrosis by inhibiting mTORC1 activity and increasing autophagic flux, reducing collagen accumulation and improving respiratory function. PMC11096666
BALB/c background SKG mice Ankylosing spondylitis model mice Oral 10 mg/kg Once daily for 6 weeks To investigate the efficacy of Ezetimibe in ankylosing spondylitis model mice, results showed that Ezetimibe significantly inhibited joint inflammation and spinal bending, and reduced the expression of proinflammatory cytokines. PMC9428320

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00101439 Hypercholesterolemia Phase 3 Completed - -
NCT00101439 - Completed - -
NCT00863265 - Completed - -
NCT00863265 Hypercholesterolemia ... More >> Coronary Heart Disease Less << Early Phase 1 Completed - United States, Utah ... More >> Center for Advance Nutrition at Utah State University Logan, Utah, United States, 84322-4715 Less <<
NCT00677248 Hypercholesterolemia Phase 2 Completed - Sweden ... More >> Karo Bio AB HUddinge, Sweden Less <<
NCT00651391 Hypercholesterolemia ... More >> Atherosclerosis Less << Phase 3 Terminated(Slow enrollment) - -
NCT00905905 Myocardial Infarction Phase 4 Completed - Brazil ... More >> Hospital de Base do Distrito Federal Brasilia, DF, Brazil, 70673103 Less <<
NCT00699023 Postprandial Lipemia ... More >> Type 2 Diabetes Less << Phase 4 Completed - Italy ... More >> Department of Clinical and Experimental Medicine, Federico II University Hospital, Naples, Italy, 80131 Less <<
NCT00299884 - Completed - Canada, Ontario ... More >> Vascular Disease Prevention and Research Centre, Hotel Dieu Hospital Kingston, Ontario, Canada, K7L 5G2 Less <<
NCT00753883 Hyperlipidemia Phase 4 Completed - -
NCT00423579 Hypercholesterolemia ... More >> Coronary Disease Less << Phase 4 Completed - -
NCT00423579 - Completed - -
NCT03051100 Hypercholesterolemia Phase 2 Completed - United States, Illinois ... More >> PMG Research of Christie Clinic Champaign, Illinois, United States, 61820 United States, North Carolina PMG Research of Cary Cary, North Carolina, United States, 27518 PMG Research of Charlotte Charlotte, North Carolina, United States, 28209 Sensenbrenner Primary Care Charlotte, North Carolina, United States, 28277 PMG Research of Hickory Hickory, North Carolina, United States, 28601 PMG Research of Raleigh Raleigh, North Carolina, United States, 27609 PMG Research of Rocky Mount Rocky Mount, North Carolina, United States, 27804 PMG Research Salisbury Salisbury, North Carolina, United States, 28144 PMG Research of Wilmington Wilmington, North Carolina, United States, 28401 United States, South Carolina PMG Research of Charleston Mount Pleasant, South Carolina, United States, 29464 United States, Virginia Hampton Roads Center for Clinical Research Virginia Beach, Virginia, United States, 23451 Less <<
NCT00909389 - Completed - -
NCT00909389 - Completed - -
NCT00481351 Coronary Heart Disease Phase 4 Completed - -
NCT01603758 Coronary Heart Disease|Cardiov... More >>ascular Disease|Dyslipidemia|Disorder of Cholesterol Metabolism Less << PHASE1 COMPLETED 2025-06-15 Washington University School o... More >>f Medicine, St. Louis, Missouri, 63110, United States Less <<
NCT00481351 - Completed - -
NCT00268697 Hypercholesterolemia Phase 3 Completed - Estonia ... More >> Tallinn, Estonia Tartu, Estonia Latvia Riga, Latvia Russian Federation Moscow, Russian Federation Saratov, Russian Federation Smolensk, Russian Federation St. Petersburg, Russian Federation Tyumen, Russian Federation Serbia Kragujevac, Serbia Less <<
NCT01370590 Hypercholesterolemia Phase 3 Completed - -
NCT01370590 - Completed - -
NCT01370603 - Completed - -
NCT00705081 - Completed - -
NCT00705081 - Completed - -
NCT00819403 Metabolic Syndrome Phase 4 Completed - United States, Maryland ... More >> VA Maryland Health Care System Baltimore, Maryland, United States, 21201 University of Maryland Medical Center Baltimore, Maryland, United States, 21202 Johns Hopkins Hospital Baltimore, Maryland, United States, 21287 Less <<
NCT01375764 - Completed - -
NCT00819403 - Completed - -
NCT01035320 Diabetes Mellitus|Impaired Ren... More >>al Function Less << PHASE4 COMPLETED 2025-06-12 Department of Medicine, Clinic... More >>al Pharmacology Unit, Karolinska University Hospital (Solna), Stockholm, 171 76, Sweden Less <<
NCT02127320 Healthy Phase 1 Completed - Korea, Republic of ... More >> Asan Medical Center Seoul, Korea, Republic of, Korea, Republic of Less <<
NCT00650689 Hypercholesterolemia ... More >> Atherosclerosis Coronary Artery Disease Less << Phase 3 Completed - -
NCT01375764 Hyperlipidemia Phase 2 Completed - -
NCT00701727 Hypercholesterolemia Phase 4 Completed - United States, Illinois ... More >> Radiant Research Chicago, Illinois, United States, 60610 Less <<
NCT00701727 - Completed - -
NCT03771053 Coronary Heart Disease Not Applicable Recruiting December 31, 2019 China, Beijing ... More >> Chinese People's Liberation Army General Hospital Recruiting Peking, Beijing, China, 100853 Contact: Geng Qian, MD ?? 086-01055499312 ?? qiangeng9396@263.net ?? Contact: Yun-dai Chen, MD ?? 086-01055499309 ?? cyundai@126.com Less <<
NCT00474123 Stable Angina Not Applicable Completed - Brazil ... More >> Heart Institute (InCor) HOSPITAL DAS CLINICAS DA FACULDADE DE MEDICINA DA UNIVERSIDADE DE SAO PAULO (HCFMUSP) Sao Paulo, Brazil, 05403-000 Less <<
NCT00474123 - Completed - -
NCT03337308 Hyperlipidemias Phase 3 Completed - United States, Iowa ... More >> PMG Research of McFarland Ames, Iowa, United States, 50010 United States, New Hampshire Foundation Cardiology Nashua, New Hampshire, United States, 03060 United States, North Carolina PMG Research of Piedmont Healthcare Statesville, North Carolina, United States, 28625 PMG Research of Wilmington Wilmington, North Carolina, United States, 28401 United States, Tennessee PMG Research of Knoxville Knoxville, Tennessee, United States, 37912 Less <<
NCT00652847 Hypercholesterolemia Phase 4 Completed - -
NCT01941836 Hypercholesterolemia Phase 2 Completed - -
NCT00651144 Hypercholesterolemia ... More >> Atherosclerosis Less << Phase 1 Completed - -
NCT00705211 - Completed - -
NCT00783263 Hypercholesterolemia Phase 3 Completed - -
NCT00783263 - Completed - -
NCT00932620 - Completed - -
NCT00932620 Hypercholesterolemia Phase 4 Completed - Greece ... More >> University Hospital of Ioannina Ioannina, Greece, 45 110 Less <<
NCT00653835 Hypercholesterolaemia ... More >> Atherosclerosis Less << Phase 4 Completed - -
NCT01370603 Hypercholesterolemia Phase 3 Completed - -
NCT00651963 Lipid Metabolism Disorder Phase 4 Completed - -
NCT00650819 Hypercholesterolemia Phase 3 Completed - -
NCT01597700 Hypercholesterolaemia Phase 1 Completed - India ... More >> GSK Investigational Site Electronics City, Bengalore, India, 560100 Less <<
NCT00704444 - Completed - -
NCT00653796 Hypercholesterolemia ... More >> Atherosclerosis Less << Phase 4 Completed - -
NCT00965055 High Cholesterol ... More >> Coronary Artery Disease Less << Phase 3 Terminated(The study was termi... More >>nated due to inability to recruit subjects. A total of 2/100 anticipated were radomized.) Less << - United States, California ... More >> UCSD Medical Center in Hillcrest Clinical Trials Facility San Diego, California, United States, 92103 Less <<
NCT01241097 Endothelial Function Not Applicable Unknown December 2011 Brazil ... More >> Escola Bahiana de Medicina e Saúde Púiblica Recruiting Salvador, Bahia, Brazil, 40000 Contact: Marilia G Rodrigues, MD ?? 55-71-3359485 ?? mgaleffi@cardiol.br ?? Contact: Paulo Roberto P Lima, student ?? 55-71-99184765 ?? prpassoslima@hotmail.com ?? Sub-Investigator: Carolina Garcez, student Less <<
NCT00817843 Metabolic Syndrome Phase 4 Completed - Netherlands ... More >> Academic Medical Center Amsterdam, Netherlands, 1005 AZ Vascular Research Center Hoorn Hoorn, Netherlands, 1624 NP Department of Vascular Medicine UMC Utrecht Utrecht, Netherlands, 3584 CX Tweesteden Ziekenhuis Waalwijk, Netherlands, 5141 BM Spain Hospital Arnau de Vilanova Lleida, Spain, E-25198 Less <<
NCT00814723 Hypercholesterolemia Phase 4 Completed - Austria ... More >> Depart. of Internal Medicine, Medical University of Graz Graz, Austria, 8036 Less <<
NCT00651404 Hypercholesterolemia ... More >> Atherosclerosis Less << Phase 3 Completed - -
NCT00650663 Hypercholesterolemia ... More >> Atherosclerosis Less << Phase 4 Completed - -
NCT00129402 Hypercholesterolemia Phase 3 Completed - -
NCT00129402 - Completed - -
NCT00652301 Cholesterol Phase 3 Completed - -
NCT03044665 Cardiovascular Diseases ... More >> Cerebrovascular Disease Peripheral Atherosclerotic Disease Less << Not Applicable Recruiting February 15, 2022 Korea, Republic of ... More >> Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine Recruiting Seoul, Korea, Republic of, 03722 Contact: Yang-Soo Jang, MD, PhD Less <<
NCT03434613 Nonalcoholic Fatty Liver Disea... More >>se Dyslipidemias Less << Phase 4 Not yet recruiting September 1, 2019 Korea, Republic of ... More >> Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes center Not yet recruiting Seoul, Korea, Republic of, 03722 Contact: Yong-ho Lee, M.D., Ph.D. ?? 82-2-2228-1943 ?? yholee@yuhs.ac Less <<
NCT02089867 Coronary Artery Disease Phase 2 Phase 3 Completed - Brazil ... More >> Jose Rocha Faria Neto Curitiba, Paraná, Brazil, 80215-901 Less <<
NCT01611883 Hypercholesterolemia Phase 4 Completed - -
NCT01611883 - Completed - -
NCT00651014 Hypercholesterolemia ... More >> Atherosclerosis Less << Phase 4 Terminated(slow subject recrui... More >>tment and lack of medical and scientific merit due to change in new standard of therapy during that same period.) Less << - -
NCT03001076 Hypercholesterolemia ... More >> Atherosclerosis Statin Adverse Reaction Less << Phase 3 Completed - United States, Texas ... More >> Georgetown, Texas, United States, 78626 Less <<
NCT02288338 Healthy Phase 1 Completed - Korea, Republic of ... More >> ChongKunDang Seoul, Korea, Republic of Less <<
NCT01103648 Prediabetes H... More >>ypercholesterolemia Inflammation Cardiovascular Risk Less << Not Applicable Completed - Brazil ... More >> Hospital do Rim e Hipertensao da UNIFESP Sao Paulo, Brazil, 04038-002 Less <<
NCT01086020 Coronary Artery Disease Phase 4 Unknown December 2012 China, Shanghai ... More >> Ruijin Hospital, Recruiting Shanghai, Shanghai, China, 200025 Contact: Ruiyan Zhang, MD ?? 862164370045 ext 665215 ?? zhangruiyan@263.net ?? Contact: Xin Chen, MD ?? 862164370045 ext 665380 ?? rjchenxin@yahoo.com.cn ?? Principal Investigator: Ruiyan Zhang, MD Less <<
NCT00319449 Hypercholesterolemia ... More >> Coronary Arteriosclerosis Less << Phase 4 Completed - -
NCT00817843 - Completed - -
NCT01584206 Sitosterolemia COMPLETED 2025-12-16 Richardson Centre for Function... More >>al Foods and Nutraceuticals, Winnipeg, Manitoba, R3T 2N2, Canada Less <<
NCT01490229 Coronary Artery Disease Phase 4 Unknown December 2016 Italy ... More >> San Raffaele Pisana Recruiting Rome, Italy, 00100 Contact: Giuseppe Marazzi, MD ?? +39 335 8381320 ?? giuseppe.marazzi@yahoo.com Less <<
NCT00319449 - Completed - -
NCT00653913 Hypercholesterolemia Phase 1 Completed - -
NCT00772551 HIV Phase 1 Completed - United Kingdom ... More >> Chelsea and Westminster Hospital NHS Foundation Trust London, United Kingdom, SW10 9NH Less <<
NCT00653276 Cholesterol Phase 1 Completed - -
NCT01950884 ?Non-alcoholic Steatohepatitis... More >> (NASH) Less << Phase 4 Unknown December 2014 Italy ... More >> Dipartimento Biomedico di Medicina Interna e Specialistica Di.Bi.M.I.S. Palermo, Italy, 90127 Less <<
NCT00202904 Hypercholesterolemia ... More >> Coronary Heart Disease Less << Phase 4 Completed - -
NCT00738985 Cardiovascular Diseases ... More >> Hyperlipidemia Less << Phase 4 Withdrawn(The study was cancel... More >>led due to budget limitations) Less << - -
NCT01766713 Non Alcoholic Steatohepatitis PHASE2 COMPLETED 2025-09-14 University of California, San ... More >>Diego, San Diego, California, 92103, United States Less <<
NCT03217409 Diabetes Mellitus and Hypercho... More >>lesterolemia Less << Phase 4 Recruiting July 2018 Korea, Republic of ... More >> Soon Chun Hyang University Hospital Cheonan Recruiting Cheonan, Korea, Republic of Soon Chun Hyang University Hospital Gumi Recruiting Gumi, Korea, Republic of Soon Chun Hyang University Hospital Bucheon Recruiting Gyeonggi-do, Korea, Republic of Soon Chun Hyang University Hospital Seoul Recruiting Seoul, Korea, Republic of Less <<
NCT01766713 Non Alcoholic Steatohepatitis PHASE2 COMPLETED 2025-09-14 University of California, San ... More >>Diego, San Diego, California, 92103, United States Less <<
NCT01008345 Coronary Artery Disease ... More >> Diabetes Less << Phase 4 Completed - Lebanon ... More >> Hotel Dieu de France Hospital Achrafieh, Beirut, Lebanon, 0000 Less <<
NCT00653445 Hypercholesterolemia ... More >> Coronary Heart Disease Atherosclerosis Less << Phase 3 Completed - -
NCT00867165 Primary Hypercholesterolemia Phase 3 Completed - -
NCT02103049 Dyslipidemia|Transplants PHASE4 COMPLETED 2025-12-15 University Medical Center Ljub... More >>ljana, Ljubljana, 1000, Slovenia Less <<
NCT00621101 Pharmacokinetics ... More >> Drug Interactions Hypercholesterolemia Immunosuppression Less << Phase 1 Completed - Germany ... More >> Department of Clinical Pharmacology Greifswald, Germany, 17487 Less <<
NCT00654095 - Completed - -
NCT03277079 Coronary Artery Disease Phase 4 Not yet recruiting March 31, 2018 Italy ... More >> Sapienza University Rome, Italy, 00161 Less <<
NCT00653523 - Completed - -
NCT01385631 ST-Segment Elevation Myocardia... More >>l Infarction Less << Phase 4 Completed - Denmark ... More >> Department of Cardiology, Odense University Hospital Odense C, Denmark, 5000 Less <<
NCT00908011 Hypercholesterolemia ... More >> HIV Infections Less << Not Applicable Completed - Canada, British Columbia ... More >> St. Paul's Hospital HIV Immunodeficiency/Metabolic Clinic Vancouver, British Columbia, Canada, V6Z 1Y6 Less <<
NCT00867165 - Completed - -
NCT00654095 Hypercholesterolemia Phase 3 Completed - -
NCT00908011 - Completed - -
NCT00704535 Primary Hypercholesterolemia|H... More >>omozygous Familial Hypercholesterolemia Less << COMPLETED 2025-04-08 -
NCT00653523 Hypercholesterolemia Phase 3 Completed - -
NCT00621699 Pharmacokinetics ... More >> Drug Interactions Hypercholesterolemia Immunosuppression Less << Phase 1 Completed - Germany ... More >> Department of Clinical Pharmacology Greifswald, Germany, 17487 Less <<
NCT02304926 Dyslipidemia Not Applicable Completed - -
NCT02289430 Healthy Phase 1 Completed - -
NCT03169985 Coronary Artery Disease Phase 4 Recruiting December 31, 2023 Korea, Republic of ... More >> Samsung Medical Center Recruiting Seoul, Korea, Republic of, 06351 Contact: Joo-Yong Hahn, MD, PhD ?? 82-2-3410-6653 ?? ichjy1@gmail.com ?? Contact: Joo Myung Lee, MD, MPH ?? 82-2-3410-1246 ?? drone80@hanmail.net Less <<
NCT02304926 - Completed - -
NCT02244944 Nonalcoholic Fatty Liver Disea... More >>se (NAFLD) Less << Phase 2 Terminated(Failure to recruit) - United States, Kentucky ... More >> University of Kentucky Medical Center Lexington, Kentucky, United States, 40536 Less <<
NCT00634140 Chronic Acalculous Cholecystit... More >>is Less << Not Applicable Withdrawn(Study was never init... More >>iated due to lack of funding support.) Less << August 2009 United States, Indiana ... More >> Indiana University Hospital Indianapolis, Indiana, United States, 46202 Less <<
NCT00651274 Atherosclerosis ... More >> Hypercholesterolemia Coronary Heart Disease Less << Phase 4 Completed - -
NCT01807078 Coronary Artery Disease Phase 4 Unknown December 2017 Italy ... More >> Sapienza University Not yet recruiting Rome, Lazio, Italy, 00161 Contact: Francesco Pelliccia, MD ?? +39064997 ext 123 ?? f.pelliccia@mclink.it ?? Contact: Giuseppe Marazzi, MD ?? +39064997 ext 123 ?? md4151@mclink.it ?? Principal Investigator: Francesco Pelliccia, MD Less <<
NCT02588235 Coronary Artery Disease Phase 4 Unknown November 2017 China, Shaanxi ... More >> Xijing Hospital, Fourth Military Medical University Recruiting Xi'an, Shaanxi, China, 710032 Contact: Dongdong Sun, M.D., Ph.D. Less <<
NCT00704535 Primary Hypercholesterolemia|H... More >>omozygous Familial Hypercholesterolemia Less << COMPLETED 2025-04-08 -
NCT02244944 - Terminated(Failure to recruit) - -
NCT02126137 Chronic Hepatitis C PHASE1 UNKNOWN 2025-03-16 Department of Gastroenterology... More >>, Pontificia Universidad Católica de Chile, Santiago, Metropolitan, 8330024, Chile Less <<
NCT00762229 Hypercholesterolemia Not Applicable Completed - United States, New York ... More >> Bronx VA Medical Center Bronx, New York, United States, 10468 Less <<
NCT02768545 Hepatitis C PHASE4 UNKNOWN 2025-06-16 Departamento de Gastroenterolo... More >>gía, Pontificia Universidad Católica de Chile, Santiago, RM, 833-0024, Chile Less <<
NCT00794677 Hypercholesterolemia Phase 4 Completed - United States, California ... More >> Cholesterol Research Center Berkeley, California, United States, 94705 Less <<
NCT00794677 - Completed - -
NCT02029625 Dyslipidemia Phase 1 Completed - Korea, Republic of ... More >> Kyungpook National Hospital Jung-gu, Daegu, Korea, Republic of, 700-721 Less <<
NCT02548936 Atherosclerosis Early Phase 1 Unknown December 2016 China, Beijing ... More >> Peking Union Medical College Hospital Beijing, Beijing, China, 100730 Less <<
NCT00762229 - Completed - -
NCT01849068 Metabolic Syndrome X Phase 3 Completed - Canada ... More >> Laval University Quebec, Canada, G1V 0A6 Less <<
NCT01849068 - Completed - -
NCT03099278 Chronic Hepatitis D PHASE2 UNKNOWN 2025-10-17 Ziauddin University Hospital, ... More >>Karachi, Sindh, 75600, Pakistan Less <<
NCT02772640 Hypercholesterolemia Phase 4 Unknown December 2016 Poland ... More >> Cardiology Department, Dr. A. Jurasz University Hospital Recruiting Bydgoszcz, Kujawsko-Pomorskie, Poland, 85-094 Contact: Karolina Obońska, MD, PhD ?? +48 52 5854023 ?? kalaobonska@op.pl Less <<
NCT03105310 Hepatitis D, Chronic Phase 2 Active, not recruiting June 2017 -
NCT02971033 Chronic Hepatitis C Phase 2 Recruiting June 30, 2020 United States, Illinois ... More >> Edward Hines Jr. VA Hospital, Hines, IL Recruiting Hines, Illinois, United States, 60141-5000 Contact: Susan L Uprichard, PhD ?? 708-202-8387 ext 25848 ?? Susan.Uprichard@va.gov ?? Principal Investigator: Susan L. Uprichard, PhD Less <<
NCT03531905 Diabetes Diab... More >>etes Mellitus, Type 2 Cholesterolemia Less << Phase 2 Recruiting May 2019 United States, California ... More >> Clinical Trials Research Recruiting Lincoln, California, United States, 95648 United States, Florida FInlay Medical Research Recruiting Miami, Florida, United States, 33126 United States, Kentucky L-MARC Research Center Recruiting Louisville, Kentucky, United States, 40213 United States, Virginia Hampton Roads Center for Clinical Research Recruiting Suffolk, Virginia, United States, 23435 Less <<
NCT02682680 Type 2 Diabetes Mellitus Phase 4 Unknown December 2017 Canada, Alberta ... More >> LMC Calgary Not yet recruiting Calgary, Alberta, Canada Contact: Akshay Jain, MD ?? 403-288-3224 ?? calgaryresearch@lmc.ca ?? Canada, Ontario LMC Barrie Recruiting Barrie, Ontario, Canada Contact: Hani Alasaad, MBBS ?? 705-737-0830 ?? barrieresearch@lmc.ca ?? LMC Brampton Recruiting Brampton, Ontario, Canada, L6S 0C9 Contact: Harpreet Bajaj, MBBS, MPH ?? 905-595-0560 ?? bramptonresearch@lmc.ca ?? LMC Etobicoke Recruiting Etobicoke, Ontario, Canada Contact: Hasnain Khandwala, MBBS ?? 416-645-1035 ?? etobicokeresearch@lmc.ca ?? LMC Markham Recruiting Markham, Ontario, Canada Contact: Nikhil Gupta, MBBS, MPH ?? 905-294-0800 ?? markhamresearch@lmc.ca ?? LMC Oakville Recruiting Oakville, Ontario, Canada Contact: David Twum-Barima, MB ChB, MSc ?? 905-337-0040 ?? oakvilleresearch@lmc.ca ?? LMC Thornhill Recruiting Thornhill, Ontario, Canada Contact: Ronald Goldenberg, MD ?? 905-763-8660 ?? thornhillresearch@lmc.ca ?? LMC Bayview Recruiting Toronto, Ontario, Canada Contact: Ronnie Aronson, MD ?? 416-645-2929 ?? torontoresearch@lmc.ca Less <<
NCT01384058 Diabetes Mellitus Type 2 ... More >> Hypercholesterolemia Less << Phase 4 Completed - Germany ... More >> Institut für Stoffwechselforschung Frankfurt, Germany, 60322 Stephan Jacob, MD Villingen-.Schwenningen, Germany, 78048 Less <<
NCT02890992 Hypercholesterolaemia Phase 2 Active, not recruiting February 22, 2019 United States, Missouri ... More >> Investigational Site Number 8400002 Saint Louis, Missouri, United States, 63110 United States, North Carolina Investigational Site Number 8400005 Charlotte, North Carolina, United States, 28204 United States, Ohio Investigational Site Number 8400001 Cincinnati, Ohio, United States, 45229 Canada Investigational Site Number 1240001 Quebec, Canada, G1V 4W2 Czechia Investigational Site Number 2030001 Brno, Czechia, 62500 Investigational Site Number 2030003 Praha 5 - Motol, Czechia, 15006 Investigational Site Number 2030002 Zlin, Czechia, 76275 France Investigational Site Number 2500001 Bron Cedex, France, 69677 Netherlands Investigational Site Number 5280001 Amsterdam, Netherlands, 1105 AZ Norway Investigational Site Number 5780001 Oslo, Norway, 0373 Russian Federation Investigational Site Number 6430001 Kemerovo, Russian Federation, 650002 Investigational Site Number 6430004 Saint-Petersburg, Russian Federation, 194100 South Africa Investigational Site Number 7100001 Parow, South Africa, 7500 Spain Investigational Site Number 7240004 A Coruna, Spain, 15001 Investigational Site Number 7240001 Madrid, Spain, 28009 Sweden Investigational Site Number 7520001 Stockholm, Sweden, 171 76 Less <<
NCT00079638 Dyslipidemia ... More >>Coronary Heart Disease Atherosclerosis Stroke Diabetes Less << Phase 4 Completed - -
NCT02755194 - Recruiting September 2019 Canada, Ontario ... More >> The Hospital for Sick Children Recruiting Toronto, Ontario, Canada, M5G1X8 Contact: Shinya Ito, MD, FRCPC ?? 416-813-7562 ?? shinya.ito@sickkids.ca Less <<
NCT00120289 Cardiovascular Diseases ... More >> Heart Diseases Cerebrovascular Accident Coronary Disease Atherosclerosis Myocardial Infarction Less << Phase 3 Terminated(AIM-HIGH was stoppe... More >>d on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.) Less << - -
NCT01660945 Hypercholesterolemia Phase 4 Completed - Korea, Republic of ... More >> Gil Medical Center Incheon, Korea, Republic of, 405-760 Less <<
NCT03214211 - Not yet recruiting June 30, 2022 Korea, Republic of ... More >> Chonnam national university hospital Not yet recruiting Gwangju, Korea, Republic of Contact: Myung-Ho Jeong, Ph.D ?? ?? myungho@chollian.net Less <<
NCT00701883 Hyperlipidemia Phase 2 Completed - -
NCT00120289 - Terminated(AIM-HIGH was stoppe... More >>d on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.) Less << - -
NCT03449784 - Recruiting May 1, 2041 France ... More >> Uhmontpellier Recruiting Montpellier, France, 34295 Contact: cyril BREUKER ?? ?? c-breuker@chu-montpellier.fr Less <<
NCT01252875 Ischemic Stroke ... More >> Transient Ischemic Attack Atherosclerotic Stenosis Less << Not Applicable Recruiting December 2019 France ... More >> BICHAT HOSPITAL Departement of Neurology Recruiting Paris, France, 75018 Contact: Pierre AMARENCO, Pr, MD, PhD ?? +33(0)1 40 25 87 26 ?? Pierre.amarenco@bch.aphp.fr ?? Principal Investigator: Pierre AMARENCO, Pr, MD, PhD ?? ?? ?? BICHAT HOSPITAL Department of neurology and stroke center Recruiting Paris, France, 75018 Contact: Pierre Amarenco, MD ?? +33 (0) 1 40 25 87 26 ext 87 24 ?? pierre.amarenco@bch.aphp.fr Less <<
NCT01308203 Coronary Artery Disease ... More >> Dyslipidemias Less << Phase 4 Terminated(Merck has decided t... More >>o discontinue all studies with extended-release niacin/laropiprant.because the HPS2-THRIVE did not meet its primary endpoint) Less << - Argentina ... More >> Hospital Italiano de Buenos Aires Buenos Aires, Argentina, C1181ACH Less <<
NCT01274559 Primary Hypercholesterolemia ... More >> Mixed Dyslipidemia Less << Phase 3 Terminated(In HPS2-THRIVE, MK-... More >>0524A did not meet the primary efficacy objective and there was a significant increase in incidence of some types of non-fatal SAEs) Less << - -
NCT01274559 - Terminated(In HPS2-THRIVE, MK-... More >>0524A did not meet the primary efficacy objective and there was a significant increase in incidence of some types of non-fatal SAEs) Less << - -
NCT03310671 - Recruiting July 18, 2018 Spain ... More >> Fernando Civeira Murillo Recruiting Zaragoza, Spain, 50009 Contact: Victoria MARCO BENEDí, RD ?? 976765500 ext 2895 ?? vmarcobenedi@gmail.com Less <<
NCT02941848 Primary Hypercholesterolemia Phase 1 Completed - -
NCT00679237 Coronary Heart Disease Not Applicable Active, not recruiting December 2024 Norway ... More >> Sorlandet Hospital Arendal, Norway Less <<
NCT02642159 Dyslipidemia Phase 4 Completed - -
NCT02055976 Hypercholesterolemia Phase 2 Completed - Japan ... More >> Maebashi Hirosegawa Clinic Maebashi, Gunma, Japan, 371-0022 Yokohama Minoru Clinic Yokohama, Kanagawa, Japan, 232-0064 Heishinkai Medical Group Incorporated OCROM Clinic Suita, Osaka, Japan, 565-0853 Meiwa Hospital Chiyoda-ku, Tokyo, Japan, 101-0041 Tokyo-Eki Center-building Clinic Chuo-ku, Tokyo, Japan, 103-0027 Heishinkai Medical Group Incorporated ToCROM Clinic Shinjuku-ku, Tokyo, Japan, 160-0022 Clinical Research Hospital Tokyo Shinjuku-ku, Tokyo, Japan, 162-0053 Oda Clinic Shinjuku-ku, Tokyo, Japan, 169-0072 Sekino Hospital Toshima-ku, Tokyo, Japan, 171-0014 Less <<
NCT00655265 Familial Hypercholesterolemia Phase 4 Completed - France ... More >> Service d'Endocrinologie, Metabolisme Prevention des Maladies Cardio-Vasculaires Paris Cedex, France Germany Kardiologie Marburg, Germany Netherlands Academic Medical Centre Amsterdam, Netherlands University Medical Centre Nijmegen, Netherlands University Medical Centre Utrecht, Netherlands TweeSteden Ziekenhius Waalwijk, Netherlands Sweden Centre for Metabolism and Endocrinology Huddinge, Sweden United Kingdom Department of Medicine, University of Manchester Manchester, United Kingdom Less <<
NCT02642159 - Completed - -
NCT01477944 - Completed - -
NCT02942602 Hyperlipidemia Not Applicable Completed - Korea, Republic of ... More >> Division of Cardiology, Department of Internal Medicine, Seoul, Korea, Republic of, 03722 Less <<
NCT00359281 Healthy Phase 2 Completed - United States, Pennsylvania ... More >> University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT03433755 Primary Hypercholesterolemia ... More >> Mixed Dyslipidemia Less << Phase 3 Not yet recruiting August 25, 2020 -
NCT01516879 - Completed - -
NCT01948648 Sitosterolemia Not Applicable Recruiting December 31, 2019 Canada, Manitoba ... More >> Richardson Center for Functional Foods and Nutraceuticals Recruiting Winnipeg, Manitoba, Canada Contact: Semone B Myrie, PhD ?? 204-272-1555 ?? myrie@cc.umanitoba.ca ?? Contact: Peter J Jones, PhD ?? 204-474-8883 ?? Peter.Jones@umanitoba.ca ?? Sub-Investigator: Semone B Myrie, PhD ?? ?? ?? Principal Investigator: Peter J Jones, PhD ?? ?? ?? Sub-Investigator: David Mymim, PhD ?? ?? ?? Sub-Investigator: Taback Shayne, PHD Less <<
NCT00090168 Hypercholesterolemia ... More >> Atherosclerotic Disease Coronary Disease Less << Phase 3 Completed - -
NCT01516879 Hypercholesterolemia Phase 3 Completed - -
NCT01420328 Inflammation Phase 3 Unknown December 2013 United States, New York ... More >> Diabetes Endocrinology Center of WNY Buffalo, New York, United States, 14209 Less <<
NCT03549260 LDL Cholesterol Phase 2 Active, not recruiting November 30, 2018 United States, Indiana ... More >> Midwest Institute For Clinical Research Indianapolis, Indiana, United States, 46260 United States, Kentucky Louisville Metabolic and Atherosclerosis Research Center Louisville, Kentucky, United States, 40213 United States, Ohio Sterling Research Group Cincinnati, Ohio, United States, 45219 The Lindner Research Center Cincinnati, Ohio, United States, 45219 Metabolic & Atherosclerosis Research Center (MARC) Cincinnati, Ohio, United States, 45227 Less <<
NCT00952770 Coronary Artery Disease Phase 4 Unknown - Korea, Republic of ... More >> Chungnam National University Hospital Recruiting Daejeon, Korea, Republic of Contact: Jae-Hyeong Park, MD, PhD ?? 82-42-280-7167 ?? jaehpark@cnuh.co.kr Less <<
NCT01070966 - Completed - -
NCT00724477 - Completed - -
NCT00359281 - Completed - -
NCT02205775 Stable Coronary Artery Disease... More >> Undergoing PCI Less << Phase 3 Terminated(difficult recruitme... More >>nt) Less << - Italy ... More >> SS. Annunziata Hospital Chieti, CH, Italy, 66100 Fondazione IRCCS Policlinico S. Matteo Pavia, PV, Italy, 27100 A.O. S. Anna e S. Sebastiano - II Università di Napoli Caserta, Italy, 81100 Azienda ASL 6 - P. Ospedaliero Livorno Livorno, Italy, 57100 Ospedale Civile G. Fornaroli Magenta, Italy, 20013 Azienda Ospedaliera - Ospedale San Paolo Milano, Italy, 20142 Less <<
NCT01070966 - Completed - -
NCT01112423 Dyslipidemia Phase 2 Completed - United States, Arkansas ... More >> Osborne Research Center Little Rock, Arkansas, United States, 72201 United States, Kansas Pra International Lenexa, Kansas, United States, 66219 United States, Ohio Sterling Research Grp, Ltd. Cincinnati, Ohio, United States, 45219 United States, Texas Cetero Research - San Antonio San Antonio, Texas, United States, 78229 United States, Virginia National Clinical Research - Norfolk, Inc. Norfolk, Virginia, United States, 23502 National Clinical Research - Richmond, Inc. Richmond, Virginia, United States, 23294 Australia, Queensland Local Institution Brisbane, Queensland, Australia, 4021 Canada, Manitoba Local Institution Winnipeg, Manitoba, Canada, R2V 4W3 Canada, Newfoundland and Labrador Local Institution Mount Pearl, Newfoundland and Labrador, Canada, A1N 1W7 Canada, Ontario Local Institution London, Ontario, Canada, N6A 5R8 Canada, Quebec Local Institution Drummondville, Quebec, Canada, J2B 7T1 Local Institution Montreal, Quebec, Canada, H3J 2V5 Less <<
NCT00724477 - Completed - -
NCT00548145 - Terminated - -
NCT00548145 Alzheimer Disease ... More >> Hypercholesterolemia Less << Not Applicable Terminated - Japan ... More >> Osaka University Hospital Suita, Osaka, Japan, 565-0871 Less <<
NCT00738972 Hypertension Phase 3 Terminated(Study terminated ea... More >>rly due to sample size, not possible to perform further statistical analysis.) Less << - -
NCT00738972 - Terminated(Study terminated ea... More >>rly due to sample size, not possible to perform further statistical analysis.) Less << - -
NCT00092807 Lipid Metabolism, Inborn Error... More >>s Heart Disease Less << Phase 3 Completed - -
NCT00559962 Hyperlipidemia Phase 2 Completed - United States, California ... More >> Scripps Clinic San Diego, California, United States, 92128 Radiant Research Santa Rosa, California, United States, 95405 United States, District of Columbia MedStar Research Institute Washington, District of Columbia, United States, 20003 United States, Illinois Radiant Research Chicago, Illinois, United States, 60610 United States, Iowa University of Iowa Iowa City, Iowa, United States, 52242 United States, Kentucky LMARC Louisville, Kentucky, United States, 40213 United States, Maine Maine Research Associates Auburn, Maine, United States, 04210 United States, Maryland Health Trends Research Baltimore, Maryland, United States, 21209 Johns Hopkins Baltimore, Maryland, United States, 21287 United States, Missouri Washington Univ. School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio Sterling Research Group Cincinnati, Ohio, United States, 45219 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 United States, Texas Baylor College of Medicine Houston, Texas, United States, 77030 Clinical Trial Network Houston, Texas, United States, 77074 dgd Research San Antonio, Texas, United States, 78229 Less <<
NCT00092820 Lipid Metabolism, Inborn Error... More >>s Heart Disease Less << Phase 3 Completed - -
NCT00132717 Hypercholesterolemia Phase 3 Completed - -
NCT02767362 Endometrial Cancer Early Phase 1 Recruiting November 2020 United States, North Carolina ... More >> University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Recruiting Chapel Hill, North Carolina, United States, 27599 Contact: Leslie Clark, MD ?? 919-843-7572 ?? leslie_clark@med.unc.edu ?? Principal Investigator: Leslie Clark, MD Less <<
NCT01890889 Cholesterol H... More >>yperlipidemia Hypercholesteremia Less << Not Applicable Unknown December 2013 United States, Texas ... More >> Integrative Health Technologies Recruiting San Antonio, Texas, United States, 78209 Contact: Patricia l Keith, BBA ?? 210-824-4200 ?? hmrcenterstudy@gmail.com ?? Contact: Mike E Gale, BS ?? 210-824-4200 ?? hmrcenterstudy@gmail.com ?? Sub-Investigator: Patricia L Keith, BBA ?? ?? ?? Sub-Investigator: Samuel C Keith, BBA ?? ?? ?? Sub-Investigator: Joel A Michalek, PhD ?? ?? ?? Sub-Investigator: Harry A Croft, MD Less <<
NCT01218204 Dyslipidaemias Phase 2 Completed - -
NCT01218204 - Completed - -
NCT00687076 Peripheral Arterial Disease Phase 4 Completed - United States, Texas ... More >> Baylor College of Medicine Houston, Texas, United States, 77030 Less <<
NCT00559962 - Completed - -
NCT00449410 Atrial Fibrillation ... More >> Neuropsychology Magnetic Resonance Imaging Inflammation Hemostasis Less << Phase 4 Completed - Netherlands ... More >> Gheorghe AM Pop Nijmegen, Netherlands, 6500 HB Less <<
NCT03110432 - Recruiting February 16, 2021 Germany ... More >> Medizinische Klinik und Poliklinik III Recruiting Dresden, Germany Contact: Andreas Birkenfeld, MD Less <<
NCT01890967 Hypercholesterolemia Phase 2 Completed - -
NCT00687076 - Completed - -
NCT00442897 Hypercholesterolemia Phase 4 Completed - -
NCT01890967 - Completed - -
NCT02260648 Hypercholesterolemia Phase 3 Terminated(Study termination d... More >>ue to insufficient efficacy.) Less << - Japan ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hyogo, Japan, 650-0021 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Ibaragi, Japan, 311-3516 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Ibaraki, Japan, 311-4153 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Kyoto, Japan, 6150035 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Osaka, Japan, 530-0001 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Saitama, Japan, 350-1305 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Shizuoka, Japan, 424-0855 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Tokyo, Japan, 103-0028 Less <<
NCT01587235 Dyslipidemia Phase 4 Withdrawn May 2014 -
NCT01043380 Hypercholesterolemia ... More >> Coronary Artery Disease Less << Phase 4 Completed - Japan ... More >> Kumamoto University Kumamoto, Japan, 8608556 Less <<
NCT03204799 - Recruiting December 16, 2018 Korea, Republic of ... More >> Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes center Recruiting Seoul, Korea, Republic of, 03722 Contact: Yong-ho Lee, M.D., Ph.D. ?? 82-2-2228-1943 ?? yholee@yuhs.ac Less <<
NCT00461630 Cardiovascular Disease ... More >> Peripheral Arterial Disease Diabetes Mellitus Coronary Heart Disease Less << Phase 3 Completed - United Kingdom ... More >> Clinical Trial Service Unit, University of Oxford Oxford, United Kingdom, OX3 7LF Less <<
NCT02260648 - Terminated(Study termination d... More >>ue to insufficient efficacy.) Less << - -
NCT00461630 - Completed - -
NCT00433823 Coronary Heart Disease ... More >> Diabetes Mellitus Non-Coronary Atherosclerotic Disease Hypercholesterolemia Less << Phase 4 Unknown - Turkey ... More >> Bolu Izzet Baysal School of Medicine Recruiting Bolu, Turkey, 14280 Contact: Mustafa Kanat, MD ?? +905385448782 ?? mustafa.kanat@gmail.com Less <<
NCT00462748 - Completed - -
NCT02460159 Hypercholesterolemia ... More >> Heterozygous Familial Hypercholesterolemia Less << Phase 3 Completed - -
NCT00408057 - Completed - Canada, Ontario ... More >> St. MIchael's Hospital Toronto, Ontario, Canada, m5g 2p9 Less <<
NCT00442897 - Completed - -
NCT03532854 Healthy Male Volunteers Phase 1 Not yet recruiting September 18, 2018 Korea, Republic of ... More >> LG chem Not yet recruiting Seoul, Gangseo-Gu, Korea, Republic of, 07795 Contact: Subin Lee ?? 02-6987-4153 ?? leesubin@lgchem.com Less <<
NCT00462748 Hypercholesterolemia Phase 3 Completed - -
NCT00738296 Cardiovascular Diseases Phase 4 Completed - -
NCT02460159 - Completed - -
NCT00110435 Type 2 Diabetes Mellitus ... More >> Hypercholesterolemia Less << Phase 3 Completed - -
NCT03355027 Atherosclerosis ... More >> Cardiovascular Diseases Less << Not Applicable Recruiting May 8, 2019 United Kingdom ... More >> Addenbrooke's Hospital Recruiting Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ Contact: Paul Cacciottolo ?? 01223256653 ?? pjc99@medschl.cam.ac.uk ?? Principal Investigator: Joseph Cheriyan, MBChB, MA, FRCP Less <<
NCT00496730 - Completed - -
NCT02550288 Hypercholesterolemia Phase 3 Completed - -
NCT01763866 Hyperlipidemia Phase 3 Completed - -
NCT02550288 - Completed - -
NCT00651560 Hyperlipidemia Phase 3 Completed - -
NCT00090298 Hypercholesterolemia Phase 3 Completed - -
NCT03750760 Myocardial Infarction ... More >> Dyslipidemias Less << Phase 4 Not yet recruiting July 2019 United Kingdom ... More >> Royal Devon & Exeter Hospital Not yet recruiting Exeter, Devon, United Kingdom, EX2 5DW Contact: Andrew Sharp, MBChB, MRCP, MD ?? ?? ?? The Royal Bournemouth General Hospital Not yet recruiting Bournemouth, Dorset, United Kingdom, BH7 7DW Contact: Terry Levy, BSc, MB ChB, FRCP ?? ?? ?? East Sussex Healthcare NHS Trust Not yet recruiting Saint Leonards-on-Sea, East Sussex, United Kingdom, TN37 7PT Contact: Robert Gerber, MBBS ?? ?? ?? Basildon Hospital Not yet recruiting Basildon, Essex, United Kingdom, SS16 5NL Contact: Rajesh Aggarwal, MB ChB, FRCP (London), MD ?? ?? ?? St Mary's Hospital Not yet recruiting London, Greater London, United Kingdom, W2 1NY Contact: Jamil Mayet, MBChB, MD, FESC, FACC, FRC ?? ?? ?? Queen Alexandra Hospital Not yet recruiting Portsmouth, Hampshire, United Kingdom, PO6 3LY Contact: Huw Griffiths, MB BS (Hons), MD, FRCP ?? ?? ?? Southampton General Hospital Not yet recruiting Southampton, Hampshire, United Kingdom, SO16 6YD Contact: Nick Curzen, BM(Hons), PhD, FRCP ?? ?? ?? Northwick Park Hospital Not yet recruiting Harrow, Middlesex, United Kingdom, HA1 3UJ Contact: Ahmed Elghamaz, MB BCh MRCP ?? ?? ?? Hull Royal Infirmary Not yet recruiting Hull, North Humberside, United Kingdom, HU3 2JZ Contact: Richard Oliver, MB BS, RFCP DM, FESC ?? ?? ?? Queens Medical Centre Not yet recruiting Nottingham, Nottinghamshire, United Kingdom, NG7 2UH Contact: Shahnaz Jamil-Copley, MBChB, MRCP, PhD ?? ?? ?? St Peters Hospital Not yet recruiting Chertsey, Surrey, United Kingdom, KT16 0PZ Contact: Sumeet Sharma, MD, MRCP, CCT ?? ?? ?? East Surrey Hospital Not yet recruiting Redhill, Surrey, United Kingdom, RH1 5RH Contact: Rashid Iqbal, MSc, MRCP, MRCPI ?? ?? ?? Freeman Hospital Not yet recruiting Newcastle Upon Tyne, Tyne And Wear, United Kingdom, NE7 7DN Contact: Vijay Kunadian, MBBS, MD, FRCP, FACC, FESC ?? ?? ?? Queen Elizabeth Medical Centre Not yet recruiting Birmingham, West Midlands, United Kingdom, B15 2TH Contact: John Townend, MBChB, MD, FRCP, FESC ?? ?? ?? City Hospital Not yet recruiting Birmingham, West Midlands, United Kingdom, B18 7QH Contact: Derek Connolly, MBChB, PhD, FRCP ?? ?? ?? Worchestershire Royal Hospital Not yet recruiting Worcester, Worcestershire, United Kingdom, WR5 1DD Contact: Jasper Trevelyan, MB ChB ?? ?? ?? Northern General Hospital Not yet recruiting Sheffield, Yorkshire, United Kingdom, S5 7AU Contact: Robert Storey, BM, DM, FRCP, FESC Less <<
NCT00541697 Diabetes Mellitus, Type 2 Phase 3 Completed - -
NCT00440154 Hypercholesterolemia Phase 2 Completed - Chile ... More >> Sanofi-Aventis Administrative Office Santiago, Chile Hungary Sanofi-Aventis Administrative Office Budapest, Hungary Korea, Republic of Sanofi-Aventis Administrative Office Seoul, Korea, Republic of Mexico Sanofi-Aventis Administrative Office Mexico, Mexico Russian Federation Sanofi-Aventis Administrative Office Moscow, Russian Federation Turkey Sanofi-Aventis Administrative Office Istanbul, Turkey Less <<
NCT00496730 Hypercholesterolemia Phase 3 Completed - -
NCT00587678 Peripheral Artery Disease Not Applicable Completed - United States, Virginia ... More >> University of Virgina Health System Charlottesville, Virginia, United States, 22908 Less <<
NCT00587678 - Completed - -
NCT02741245 Hypercholesterolemia Phase 3 Completed - -
NCT01520077 Alopecia Areata Phase 1 Completed - United States, Florida ... More >> University of Miami Miami, Florida, United States, 33136 Less <<
NCT02741245 - Completed - -
NCT02445352 Primary Hypercholesterolemia Phase 3 Completed - Korea, Republic of ... More >> Severance Hospital Seodaemun-gu, Seoul, Korea, Republic of, 120-752 Less <<
NCT00092716 Hypercholesterolemia Phase 3 Completed - -
NCT00092586 Hypercholesterolemia Phase 3 Completed - -
NCT03543774 Hypercholesterolemia ... More >> Chronic Kidney Diseases Less << Phase 4 Recruiting September 15, 2019 Vietnam ... More >> Hue University of Medicine and Pharmacy Recruiting Hue, Thua Thien Hue, Vietnam, 0234 Contact: Nguyen Thanh Thao ?? 84.234.3822873 ?? hcmp@huemed-univ.edu.vn ?? Contact: Nguyen Thanh Thao ?? 84.234.3822873 ?? thaonrad@gmail.com ?? Principal Investigator: Duong Thi Ngoc Lan, Master ?? ?? ?? Sub-Investigator: Le Van An, A/Professor Less <<
NCT01763866 - Completed - -
NCT00413972 Hypercholesterolemia Phase 3 Completed - -
NCT00413972 - Completed - -
NCT02227784 Hyperlipidemia Phase 3 Terminated(Study termination d... More >>ue to program termination.) Less << - -
NCT00157911 Hypercholerolemia Phase 3 Completed - -
NCT00092898 Lipid Metabolism, Inborn Error... More >>s Heart Disease Less << Phase 3 Completed - -
NCT02451098 Hyperlipidemia Phase 3 Completed - Korea, Republic of ... More >> The catholic university of korea seoul st. Mary's hospital Seoul, Korea, Republic of Less <<
NCT00092664 Hypercholesterolemia Phase 3 Completed - -
NCT00092599 Hypercholesterolemia ... More >> Coronary Disease Less << Phase 3 Completed - -
NCT01077830 - Completed - -
NCT00092612 Hypercholesterolemia ... More >> Coronary Disease Less << Phase 3 Completed - -
NCT00092625 Hypercholesterolemia ... More >> Coronary Disease Less << Phase 3 Completed - -
NCT00092638 Hypercholesterolemia ... More >> Coronary Disease Less << Phase 3 Completed - -
NCT02227784 - Terminated(Study termination d... More >>ue to program termination.) Less << - -
NCT00093899 Hyperlipidemia ... More >> Hypercholesterolemia Hypertriglyceridemia Less << Phase 3 Completed - -
NCT00566267 Hyperlipidemia Phase 2 Phase 3 Completed - -
NCT00762164 Hypercholesterolemia Phase 4 Completed - United States, New York ... More >> Bronx VA Medical Center Bronx, New York, United States, 10468 Less <<
NCT00762164 - Completed - -
NCT01414192 - Completed - -
NCT01414192 - Completed - -
NCT01857843 Acute Coronary Syndrome Phase 4 Completed - Korea, Republic of ... More >> Severance Hospital Seoul, Korea, Republic of, 120-752 Less <<
NCT01730040 Hypercholesterolemia Phase 3 Completed - -
NCT00092677 Aortic Stenosis Phase 3 Completed - -
NCT01730040 - Completed - -
NCT02547402 Acute Kidney Injury Phase 1 Completed - United States, Michigan ... More >> Jasper Clinical Research & Development, Inc. Kalamazoo, Michigan, United States, 49007 Less <<
NCT01154036 Hypercholesterolemia Phase 3 Completed - -
NCT03768427 Hypercholesterolemia Phase 3 Not yet recruiting January 29, 2021 -
NCT00092677 - Completed - -
NCT01154036 - Completed - -
NCT02730689 Healthy Volunteers Phase 1 Completed - -
NCT00092560 Hypercholesterolemia ... More >> Hypertriglyceridemia Less << Phase 3 Completed - -
NCT02534376 Prostate Cancer Early Phase 1 Recruiting February 2020 United States, California ... More >> Cedars Sinai Medical Center Recruiting Los Angeles, California, United States, 90048 Contact: Jenny Park, MPH ?? 310-423-8762 ?? jenny.park@cshs.org ?? Principal Investigator: Hyung L Kim, MD Less <<
NCT02501200 Healthy Phase 1 Completed - -
NCT00395603 Cardiovascular Diseases ... More >> Diabetes Mellitus Less << Phase 3 Terminated(This study was term... More >>inated early due to poor recruitment.) Less << - -
NCT01077830 - Completed - -
NCT02461004 Healthy Phase 1 Completed - Korea, Republic of ... More >> The Korea University Anam Hospital Seoul, Korea, Republic of Less <<
NCT02584504 Hypercholesterolemia Phase 3 Completed - Japan ... More >> Investigational Site Number 392028 Ageo-Shi, Japan Investigational Site Number 392007 Chuo-Ku, Japan Investigational Site Number 392029 Chuo-Ku, Japan Investigational Site Number 392014 Fukui-Shi, Japan Investigational Site Number 392023 Hachioji-Shi, Japan Investigational Site Number 392013 Itoshima-Shi, Japan Investigational Site Number 392010 Kanazawa-Shi, Japan Investigational Site Number 392024 Kasuga-Shi, Japan Investigational Site Number 392004 Kawanishi-Shi, Japan Investigational Site Number 392015 Kitakyushu-Shi, Japan Investigational Site Number 392005 Komatsu-Shi, Japan Investigational Site Number 392032 Matsudo-Shi, Japan Investigational Site Number 392017 Matsumoto-Shi, Japan Investigational Site Number 392003 Mito-Shi, Japan Investigational Site Number 392018 Morioka-Shi, Japan Investigational Site Number 392009 Moriya-Shi, Japan Investigational Site Number 392006 Nagoya-Shi, Japan Investigational Site Number 392011 Nagoya-Shi, Japan Investigational Site Number 392019 Nagoya-Shi, Japan Investigational Site Number 392025 Nagoya-Shi, Japan Investigational Site Number 392027 Osaka-Shi, Japan Investigational Site Number 392030 Sakura-Shi, Japan Investigational Site Number 392016 Shinagawa-Ku, Japan Investigational Site Number 392001 Shinjuku-Ku, Japan Investigational Site Number 392008 Shinjuku-Ku, Japan Investigational Site Number 392012 Shizuoka-Shi, Japan Investigational Site Number 392002 Suita-Shi, Japan Investigational Site Number 392031 Suita-Shi, Japan Investigational Site Number 392020 Toyonaka-Shi, Japan Investigational Site Number 392022 Yao-Shi, Japan Less <<
NCT01047683 Hypertriglyceridemia Phase 3 Completed - -
NCT01047501 Hypertriglyceridemia Phase 3 Completed - -
NCT02584504 - Completed - -
NCT01492361 Cardiovascular Diseases Phase 3 Completed - -
NCT02378064 Inflammation Plaque, Atheroscl... More >>erotic Coronary Disease Renin-Angiotensin System Less << Phase 4 Completed - Korea, Republic of ... More >> Asan Medical Center Seoul, Korea, Republic of Less <<
NCT02023879 Hypercholesterolemia Phase 3 Completed - -
NCT03430284 Diabetes Mellitus, Type 2 Phase 4 Recruiting December 31, 2020 China, Shandong ... More >> Shandong Provincial Hospital Not yet recruiting Jinan, Shandong, China, 250021 Contact: Shanshan Shao ?? +8653168776094 ?? shaoshanshan11@126.com ?? Shandong Provincial Hospital Recruiting Jinan, Shandong, China Less <<
NCT03510884 Hypercholesterolaemia Phase 3 Recruiting March 2022 -
NCT01666067 Hypercholesterolemia Phase 4 Completed - Korea, Republic of ... More >> Gil Medical Center Incheon, Korea, Republic of, 405-760 Less <<
NCT02023879 - Completed - -
NCT01266876 - Completed - -
NCT02984982 Hypercholesterolemia ... More >> Acute Coronary Syndrome Less << Phase 4 Completed - Japan ... More >> Investigational Site Number 392026 Bunkyoku-ku, Japan Investigational Site Number 392022 Chiyoda-ku, Japan Investigational Site Number 392032 Fujisawa-shi, Japan Investigational Site Number 392004 Fukui-shi, Japan Investigational Site Number 392007 Fukuoka-shi, Japan Investigational Site Number 392048 Fukuoka-shi, Japan Investigational Site Number 392008 Gifu-shi, Japan Investigational Site Number 392039 Hiroshima-shi, Japan Investigational Site Number 392028 Isehara-shi, Japan Investigational Site Number 392036 Itabashi-ku, Japan Investigational Site Number 392037 Itabashi-ku, Japan Investigational Site Number 392024 Izumisano-shi, Japan Investigational Site Number 392013 Izunokuni-shi, Japan Investigational Site Number 392020 Kawaguchi-shi, Japan Investigational Site Number 392041 Kisarazu-shi, Japan Investigational Site Number 392009 Kitakyushu-shi, Japan Investigational Site Number 392034 Kitakyushu-shi, Japan Investigational Site Number 392044 Kochi-shi, Japan Investigational Site Number 392002 Kumamoto-shi, Japan Investigational Site Number 392011 Kumamoto-shi, Japan Investigational Site Number 392003 Kurashiki-shi, Japan Investigational Site Number 392018 Matsuyama-shi, Japan Investigational Site Number 392021 Morioka-shi, Japan Investigational Site Number 392017 Nagakute-shi, Aichi, Japan Investigational Site Number 392047 Nagaoka-shi, Japan Investigational Site Number 392038 Nagoya-shi, Japan Investigational Site Number 392042 Nagoya-shi, Japan Investigational Site Number 392033 Okayama-shi, Japan Investigational Site Number 392006 Osaka-shi, Japan Investigational Site Number 392010 Osaka-shi, Japan Investigational Site Number 392045 Osaka-shi, Japan Investigational Site Number 392046 Osaka-shi, Japan Investigational Site Number 392015 Sagamihara-shi, Japan Investigational Site Number 392019 Sakai-shi, Japan Investigational Site Number 392035 Sapporo-shi, Japan Investigational Site Number 392001 Tenri-shi, Japan Investigational Site Number 392016 Toyoake-shi, Japan Investigational Site Number 392025 Tsukuba-shi, Japan Investigational Site Number 392040 Tsukuba-shi, Japan Investigational Site Number 392005 Wakayama-shi, Japan Investigational Site Number 392027 Yokohama-shi, Japan Investigational Site Number 392043 Yokohama-shi, Japan Less <<
NCT03510715 Hypercholesterolemia Phase 3 Recruiting June 2020 United States, California ... More >> Investigational Site Number 8400004 Recruiting Los Angeles, California, United States, 90027 Austria Investigational Site Number 0400001 Recruiting Wien, Austria, 1090 Brazil Investigational Site Number 0760001 Recruiting Sao Paulo, Brazil, 05403-000 Canada Investigational Site Number 1240002 Recruiting Montreal, Canada, H3T 1C5 Investigational Site Number 1240001 Recruiting Quebec, Canada, G1V 4W2 Denmark Investigational Site Number 2080001 Recruiting Viborg, Denmark, 8800 France Investigational Site Number 2500001 Recruiting Bron Cedex, France, 69677 Italy Investigational Site Number 3800001 Recruiting Palermo, Italy, 90127 Mexico Investigational Site Number 4840006 Recruiting Oaxaca, Mexico, 68000 Netherlands Investigational Site Number 5280001 Recruiting Amsterdam, Netherlands, 1105 AZ Norway Investigational Site Number 5780001 Recruiting Oslo, Norway, 0373 Russian Federation Investigational Site Number 6430002 Recruiting Kemerovo, Russian Federation, 650002 Slovenia Investigational Site Number 7050001 Recruiting Ljubljana, Slovenia, 1000 Spain Investigational Site Number 7240001 Recruiting A Coruna, Spain, 15001 Taiwan Investigational Site Number 1580001 Recruiting Taipei, Taiwan, 112 Turkey Investigational Site Number 7920002 Recruiting Ankara, Turkey, 06500 Investigational Site Number 7920001 Recruiting Izmir, Turkey, 35040 Less <<
NCT01266876 Hypercholesterolemia Phase 2 Completed - -
NCT00099684 HIV Infections COMPLETED 2025-05-07 University of Alabama at Birmi... More >>ngham, Birmingham, Alabama, 35924-2050, United States|UCLA School of Medicine, Los Angeles, California, 77555-0435, United States|University of Southern California, Los Angeles, California, 90033-1079, United States|University of California, San Diego Antiviral Research Center, San Diego, California, 92103, United States|San Francisco General Hospital, San Francisco, California, 94110, United States|San Mateo County AIDS Program, Stanford, California, 94305-5107, United States|Santa Clara Valley Medical Center, Stanford, California, 94305-5107, United States|Stanford University, Stanford, California, 94305-5107, United States|Willow Clinic, Stanford, California, 94305-5107, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|University of Miami, Miami, Florida, 33136-1013, United States|University of Hawaii, Honolulu, Hawaii, 96816-2396, United States|Feinberg School of Medicine, HIV/ACTU, Chicago, 60611-3015, Illinois, 60611-3015, United States|Rush-Presbyterian/St. Lukes (Chicago), Chicago, Illinois, 60611-3015, United States|Cook County Hospital Core Center, Chicago, Illinois, 60612, United States|Indiana University Hospital, Indianapolis, Indiana, 46202-5250, United States|Wishard Hospital, Indianapolis, Indiana, 46202, United States|University of Minnesota, Minneapolis, Minnesota, 55455-0392, United States|Nebraska Health System, Omaha, Nebraska, 68198-5130, United States|SUNY - Buffalo (Rochester), Buffalo, New York, 14215, United States|Beth Israel Medical Center, New York, New York, 10003, United States|Chelsea Clinic, New York, New York, 10011, United States|NYU/Bellevue, New York, New York, 10016-6481, United States|The Cornell Clinical Trials Unit, New York, New York, 10021, United States|Columbia University, New York, New York, 10032-3784, United States|Community Health Network, Inc., Rochester, New York, 14642-0001, United States|University of Rochester Medical Center, Rochester, New York, 14642-0001, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, 45267-0405, United States|MetroHealth Medical Center, Cleveland, Ohio, 44109-1998, United States|Ohio State University, Columbus, Ohio, 43210, United States|Presbyterian Medical Center - Univ. of PA, Philadelphia, Pennsylvania, 19104, United States|University of Pennsylvania, Philadelphia, Philadelphia, Pennsylvania, 19104, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15213-2582, United States|Rhode Island Hospital, Providence, Rhode Island, 02906, United States|Stanley Street Treatment and Resource, Providence, Rhode Island, 02906, United States|The Miriam Hospital, Providence, Rhode Island, 02906, United States|Comprehensive Care Clinic, Nashville, Tennessee, 37203, United States|Dallas VA Medical Center, Dallas, Texas, 75235-9173, United States|University of Texas, Galveston, Galveston, Texas, 77555-0435, United States|University of Washington (Seattle), Seattle, Washington, 98104, United States|University of Puerto Rico, San Juan, 00936-5067, Puerto Rico Less <<
NCT01381679 Hypercholesterolemia COMPLETED 2025-12-10 -
NCT00485121 Metabolic Syndrome|Obesity|Cor... More >>onary Artery Disease Less << COMPLETED 2025-04-09 Partners Research, Brampton, O... More >>ntario, L6V 1B4, Canada Less <<
NCT00376246 Endothelial Dysfunction PHASE4 COMPLETED 2025-04-08 -
NCT01068093 Coronary Artery Disease PHASE4 UNKNOWN 2025-10-15 Yokohama City University Medic... More >>al Center, Yokohama, Kanagawa, 231-0045, Japan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.44mL

0.49mL

0.24mL

12.21mL

2.44mL

1.22mL

24.42mL

4.88mL

2.44mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Clader JW. The discovery of ezetimibe: a view from outside the receptor. J Med Chem. 2004 Jan 1;47(1):1-9.

[2]van Heek M, Farley C, et al. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol. 2001 Sep;134(2):409-17.

[3]Lee DH, Han DH, Nam KT, Park JS, Kim SH, Lee M, Kim G, Min BS, Cha BS, Lee YS, Sung SH, Jeong H, Ji HW, Lee MJ, Lee JS, Lee HY, Chun Y, Kim J, Komatsu M, Lee YH, Bae SH. Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis. Free Radic Biol Med. 2016 Oct;99:520-532

[4]Chang E, Kim L, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, Park CY. Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats. World J Gastroenterol. 2015 Jul 7;21(25):7754-63

[5]Zhang Y, Liu J, Li S, Xu RX, Sun J, Li JJ. Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats. Lipids Health Dis. 2014 Feb 18;13:35

[6]Kiourtzidis M, Kühn J, Schutkowski A, Baur AC, Hirche F, Stangl GI. Inhibition of Niemann-Pick C1-like protein 1 by ezetimibe reduces uptake of deuterium-labeled vitamin D in mice. J Steroid Biochem Mol Biol. 2020 Mar;197:105504

[7]Tie C, Gao K, Zhang N, Zhang S, Shen J, Xie X, Wang JA. Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition. PLoS One. 2015 Nov 10;10(11):e0142430

 

Historical Records

Categories